Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018;17(3):216-232.
doi: 10.2174/1871527317666180412153612.

N-3 (Omega-3) Fatty Acids: Effects on Brain Dopamine Systems and Potential Role in the Etiology and Treatment of Neuropsychiatric Disorders

Affiliations
Review

N-3 (Omega-3) Fatty Acids: Effects on Brain Dopamine Systems and Potential Role in the Etiology and Treatment of Neuropsychiatric Disorders

Michelle Healy-Stoffel et al. CNS Neurol Disord Drug Targets. 2018.

Abstract

Background & objective: A number of neuropsychiatric disorders, including Parkinson's disease, schizophrenia, attention deficit hyperactivity disorder, and, to some extent, depression, involve dysregulation of the brain dopamine systems. The etiology of these diseases is multifactorial, involving genetic and environmental factors. Evidence suggests that inadequate levels of n-3 (omega- 3) polyunsaturated fatty acids (PUFA) in the brain may represent a risk factor for these disorders. These fatty acids, which are derived from the diet, are a major component of neuronal membranes and are of particular importance in brain development and function. Low levels of n-3 PUFAs in the brain affect the brain dopamine systems and, when combined with appropriate genetic and other factors, increase the risk of developing these disorders and/or the severity of the disease. This article reviews the neurobiology of n-3 PUFAs and their effects on dopaminergic function.

Conclusion: Clinical studies supporting their role in the etiologies of diseases involving the brain dopamine systems and the potential of n-3 PUFAs in the treatment of these disorders are discussed.

Keywords: Dopamine; Parkinson's disease; attention deficit hyperactivity disorder; depression; omega-3; docosahexaenoic acid; schizophrenia..

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest

The authors have no conflicts of interest with respect to this work.

Figures

Fig. 1.
Fig. 1.
Biosynthesis of n-3 and n-6 PUFA.

Similar articles

Cited by

References

    1. Sun GY, Simonyi A, Fritsche KL, Chuang DY, Hannink M, Gu Z, et al. Docosahexaenoic acid (DHA): An essential nutrient and a nutraceutical for brain health and diseases. Prostaglandins Leukot Essent Fatty Acids 2017; S0952–3278: 30213–7. - PMC - PubMed
    1. Willatts P, Forsyth JS, DiModugno MK, Varma S, Colvin M. Effect of long-chain polyunsaturated fatty acids in infant formula on problem solving at 10 months of age. Lancet 1998; 352: 688–91. - PubMed
    1. Birch EE, Garfield S, Hoffman DR, Uauy R, Birch DG. A randomized controlled trial of early dietary supply of long-chain polyunsaturated fatty acids and mental development in term infants. Dev Med Child Neurol 2000; 42: 174–81. - PubMed
    1. Whelan J. (n-6) and (n-3) Polyunsaturated fatty acids and the aging brain: food for thought. J Nutr 2008; 138: 2521–2. - PubMed
    1. Dyall S, Michael-Titus A. Neurological benefits of omega-3 fatty acids. Neuromolecular Med 2008; 10: 219–35. - PubMed

Publication types